Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of mRNA-1345 RSV Vaccine in High-Risk Adults and Solid Organ Transplant Recipients
NCT06067230Phase 3Completed
- Sponsor
- Moderna Inc
- Start
- Oct 2023
- Primary completion
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 4
01
Overview
Phase 3, open-label trial of RNA-100-AR02 in respiratory syncytial virus infection (RSV) (3 arms), sponsored by Moderna Inc. Primary endpoints: Number of Participants with Solicited Local and Systemic Adverse Reactions, Number of Participants with Unsolicited Adverse Events and 3 more. Started Oct 2023; status: completed.
02
Drugs
RNA-100-AR02
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06067230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06067230.